Biogen Inc (BIIB) is a biotechnology company specializing in the discovery, development, and commercialization of therapies for neurological and neurodegenerative diseases. As an investor, it is crucial to have a comprehensive understanding of the technical analysis of BIIB stock. This analysis involves evaluating various indicators that provide insights into the stock's performance and potential trends.

One commonly used technical indicator is the Relative Strength Index (RSI). The RSI assesses the stock's momentum and overbought or oversold conditions. It ranges from 0 to 100, with values above 70 indicating overbought conditions and values below 30 indicating oversold conditions. By analyzing the RSI of BIIB stock, investors can gain insights into potential reversals or continuations of trends.

Biogen  (BIIB) Technical Analysis

Explore the technical analysis of Biogen Inc (BIIB) stock using key indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the stock's performance and trends. Understand market conditions and make informed investment decisions.

Biogen Inc (BIIB) Technical Analysis: Stock Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	49.95	Neutral	52.6%
auto_graphMACD	0.64	Neutral	-78.4%
auto_graphCCI	17.26	Neutral	158.6%
auto_graphADX	11.42	Neutral	-39.3%
auto_graphATR	2.89	Buy	-
auto_graphWILLR	-50.24	Neutral	126.1%
auto_graphROC	31.53	Neutral	-32.6%
auto_graphSTOCHRSI	0.00	Buy	11.2%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Biogen (BIIB) Technical Analysis

Keep an eye on Biogen

Frequently Asked Questions

What are the technical signals for Biogen (BIIB) stock based on the last 30 days?

Take Your Investments to a Whole New Level